MacroGenics (MGNX) News Today $1.56 -0.23 (-12.85%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC WainwrightHC Wainwright dropped their target price on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday.March 26 at 8:34 AM | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Average PT from BrokeragesMarch 26 at 1:53 AM | americanbankingnews.comMacroGenics price target lowered to $2 from $4 at H.C. WainwrightMarch 25 at 10:32 PM | markets.businessinsider.comStockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to HoldMarch 23 at 1:39 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have been given an average rating of "Hold" by the eleven research firms that are covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendatioMarch 23 at 12:12 AM | marketbeat.comMacroGenics (NASDAQ:MGNX) Rating Lowered to "Hold" at StockNews.comStockNews.com cut shares of MacroGenics from a "buy" rating to a "hold" rating in a research report on Friday.March 22, 2025 | marketbeat.comMacroGenics Provides Update on Corporate Progress and 2024 Financial ResultsMarch 22, 2025 | finance.yahoo.comMacroGenics (NASDAQ:MGNX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPSMacroGenics (NASDAQ:MGNX - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The company had revenue of $49.40 million during the quarter, compared to analysts' expectations of $34.17 million.March 22, 2025 | marketbeat.comQ4 2024 MacroGenics Inc Earnings CallMarch 21, 2025 | uk.finance.yahoo.comBarclays Sticks to Their Buy Rating for MacroGenics (MGNX)March 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Receives a Hold from Stifel NicolausMarch 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Gets a Hold from TD CowenMarch 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | msn.comMacroGenics, Inc. (MGNX) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comMacroGenics (MGNX) to Release Quarterly Earnings on ThursdayMacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Thursday, March 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673061)March 13, 2025 | marketbeat.comMacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference CallMarch 6, 2025 | globenewswire.comMacroGenics CEO departure date extended amid search for successorFebruary 28, 2025 | uk.investing.comMacroGenics: Stacking Up A Lot Of HeadwindsFebruary 27, 2025 | seekingalpha.comMacroGenics to Participate in Upcoming Investor ConferencesFebruary 27, 2025 | globenewswire.comMacroGenics (MGNX) to Release Earnings on ThursdayMacroGenics (NASDAQ:MGNX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Here's What HappenedMacroGenics (NASDAQ:MGNX) Shares Pass Below 200-Day Moving Average - Time to Sell?February 22, 2025 | marketbeat.comMacrogenics IncFebruary 18, 2025 | money.usnews.comThe past year for MacroGenics (NASDAQ:MGNX) investors has not been profitableFebruary 17, 2025 | finance.yahoo.comMacrogenics Stock Hits 52-Week Low at $2.91 Amid Sharp DeclineFebruary 3, 2025 | msn.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have earned a consensus recommendation of "Hold" from the eleven brokerages that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a hold recommendation, two have assigned a bFebruary 3, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)JPMorgan Chase & Co. cut its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 32.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 324,902 shares of the biopharmaceutical company's stock after selling 155,359 shares during the period.January 26, 2025 | marketbeat.comMacrogenics Stock Hits 52-Week Low at $2.95 Amid Market ChallengesJanuary 18, 2025 | msn.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by AnalystsMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has earned an average recommendation of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy raJanuary 9, 2025 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Hold" by BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received a consensus recommendation of "Hold" from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have assigned a buyDecember 15, 2024 | marketbeat.comMGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmDecember 10, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Buys 147,438 Shares of MacroGenics, Inc. (NASDAQ:MGNX)Jacobs Levy Equity Management Inc. grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 35.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 566,328 shares of the biopharmaceutical company's stock after acquiring aDecember 8, 2024 | marketbeat.comMacroGenics to Participate in Upcoming Investor ConferenceDecember 2, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Boosts Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 39.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 661,914 shares of the biopharmaceuticNovember 26, 2024 | marketbeat.comMacroGenics Announces Leadership Transition in Financial RolesNovember 21, 2024 | markets.businessinsider.comMacroGenics, Inc. (MGNX) Shareholder Alert: Grabar Law Office Investigates Claims on Your BehalfNovember 21, 2024 | markets.businessinsider.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from AnalystsMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has earned an average rating of "Hold" from the eleven analysts that are currently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assignedNovember 20, 2024 | marketbeat.comNotice to MacroGenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Claims on Your BehalfNovember 14, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for MacroGenics Issued By B. RileyMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at B. Riley issued their FY2024 earnings estimates for shares of MacroGenics in a research report issued on Wednesday, November 6th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of $0.00 per sharNovember 11, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Upgraded to Buy at StockNews.comStockNews.com upgraded MacroGenics from a "sell" rating to a "buy" rating in a research report on Sunday.November 10, 2024 | marketbeat.comFY2024 EPS Estimates for MacroGenics Boosted by AnalystMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Research analysts at HC Wainwright raised their FY2024 earnings estimates for shares of MacroGenics in a research note issued on Wednesday, November 6th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earniNovember 8, 2024 | marketbeat.comLeerink Partnrs Forecasts Increased Earnings for MacroGenicsMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Leerink Partnrs upped their FY2024 EPS estimates for MacroGenics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings of ($1.24) per share for the year, upNovember 8, 2024 | marketbeat.comAttention Macrogenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Potential Claims on Your BehalfNovember 8, 2024 | markets.businessinsider.comMacroGenics downgraded to market perform by JMP, price target removedNovember 7, 2024 | msn.comMacroGenics (MGNX) was downgraded to a Hold Rating at JMP SecuritiesNovember 7, 2024 | markets.businessinsider.comMacroGenics (NASDAQ:MGNX) Downgraded to Market Perform Rating by JMP SecuritiesJMP Securities cut MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday.November 7, 2024 | marketbeat.comMacroGenics’ Transition Phase: Balancing Potential and Uncertainty Amid Leadership and Pipeline DevelopmentsNovember 7, 2024 | markets.businessinsider.comMacrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic DevelopmentsNovember 7, 2024 | finance.yahoo.comMacroGenics’ Strategic Moves and Promising Pipeline Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comMacroGenics (MGNX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comMacroGenics to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.com Remove Ads Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Media Mentions By Week MGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼-0.140.88▲Average Medical News Sentiment MGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼177▲MGNX Articles Average Week Remove Ads Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Trevi Therapeutics News Akebia Therapeutics News ABIVAX Société Anonyme News Altimmune News Keros Therapeutics News Oruka Therapeutics News Phathom Pharmaceuticals News Autolus Therapeutics News Tourmaline Bio News Stoke Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThe Crypto Market is About to Change LivesWe’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGNX Stock Free MGNX Stock Alerts